ArticleFrontiers in genetics2025
High-precision lung cancer subtype diagnosis on imbalanced exosomal data via Exo-LCClassifier.
Article in Frontiers in genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objective: Gene expression analysis plays a critical role in lung cancer research, offering molecular feature-based diagnostic insights that are particularly effective in distinguishing lung cancer subtypes. However, the high dimensionality and inherent imbalance of gene expression data create significant challenges for accurate diagnosis. This study aims to address these challenges by proposing an innovative deep learning-based method for predicting lung cancer subtypes. Methods: We propose a method called Exo-LCClassifier, which integrates feature selection, one-dimensional convolutional neural networks (1D CNN), and an improved Wasserstein Generative Adversarial Network (WGAN). First, differential gene expression analysis was performed using DESeq2 to identify significantly expressed genes from both normal and tumor tissues. Next, the enhanced WGAN was applied to augment the dataset, addressing the issue of sample imbalance and increasing the diversity of effective samples. Finally, a 1D CNN was used to classify the balanced dataset, thereby improving the model's diagnostic accuracy. Results: The proposed method was evaluated using five-fold cross-validation, achieving an average accuracy of 0.9766 ± 0.0070, precision of 0.9762 ± 0.0101, recall of 0.9827 ± 0.0050, and F1-score of 0.9793 ± 0.0068. On an external GEO lung cancer dataset, it also showed strong performance with an accuracy of 0.9588, precision of 0.9558, recall of 0.9678, and F1-score of 0.9616. Conclusion: This study addresses the critical challenge of imbalanced learning in lung cancer gene expression analysis through an innovative computational framework. Our solution integrates three advanced techniques: (1) DESeq2 for differential expression analysis, (2) WGAN for data augmentation, and (3) 1D CNN for feature learning and classification. The source codes are publicly available at: https://github.com/lanlinxxs/Exo-classifier.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.